|
|
Upfront Briefing
Astellas walked away from its CytomX T-cell engager collaboration, putting fresh focus on how quickly partnered pipeline value can unwind — especially when a biotech is also leaning on new data and a financing window.
Elsewhere, Structure Therapeutics posted positive 44-week data for its obesity pill aleniglipron as it advances toward Phase 3, while Roche expanded its NVIDIA partnership to build an “AI factory” for drugs + diagnostics.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,699.4 |
+1.0% |
(2.1%) |
| Nasdaq 100 |
24,655.3 |
+1.1% |
(2.4%) |
| Russell 2000 |
2,503.3 |
+0.9% |
+0.9% |
| Healthcare (XLV) |
151.0 |
+0.8% |
(2.4%) |
| Biotech (XBI) |
123.9 |
+1.7% |
+1.6% |
| Nasdaq Biotech (NBI) |
5,774.2 |
+1.0% |
+1.2% |
| Clinical Trials (BBC) |
41.5 |
+2.1% |
+7.6% |
|
- Risk bounced as macro pressure eased: a sharp intraday drop in oil and softer Treasury yields helped drive the S&P's best session in five weeks, lifting duration-sensitive growth and biotech beta.
- Biotech outperformed defensives on the rebound: XBI (+1.7%) and BBC (+2.1%) out-ran XLV (+0.8%), suggesting investors leaned back into SMID-cap and clinical-stage risk rather than hiding in large-cap healthcare.
The Big 3
|
1
|
Astellas exits CytomX T-cell engager collaboration
|
- Astellas walked away from its CytomX T-cell engager collaboration, ending a pact signed in 2020 that carried $80M upfront and up to $1.6B in milestones.
- Why it matters: This is a live reminder that older platform-style discovery alliances are not guaranteed to mature into durable value. For investors, the read-through is twofold: partnered pipeline value can evaporate faster than modeled, and the timing is especially relevant with CytomX simultaneously leaning on fresh clinical data and the equity markets for financing.
- Source: Fierce Biotech
- More: BioPharma Dive; Offering PR
|
|
2
|
Structure Therapeutics obesity pill advances to Phase 3
|
- Structure Therapeutics' obesity pill, aleniglipron, showed positive 44-week data, positioning it to advance toward Phase 3 trials.
- Why it matters: These data move aleniglipron from “interesting oral GLP-1” toward a credible late-stage scarcity asset: continued weight loss at 44 weeks, no obvious plateau and manageable discontinuations improve Phase 3 confidence, strengthen partnering/M&A leverage, and raise the competitive bar for oral obesity programs behind Lilly and Novo.
- Source: BioPharma Dive
- More: BioCentury
|
| 3 | Roche expands NVIDIA partnership for AI drug, diagnostics development |
- Roche is expanding its partnership with NVIDIA to create an "AI factory" aimed at accelerating drug and diagnostics development, signaling increased investment in AI by big pharma.
- Why it matters: Roche is signaling that compute is becoming core R&D infrastructure, not a side experiment. For investors, the key read-through is that AI advantage will accrue less to companies signing headline partnerships and more to those with proprietary data, balance-sheet capacity and enough internal workflow adoption to turn GPU spend into faster target selection, biomarker work and clinical execution.
- Source: Fierce Biotech
- More: PR
|
Everything Else that broke
- A federal judge temporarily halted the CDC’s planned childhood vaccine schedule overhaul and related actions, preserving the prior commercial framework for vaccine makers for now. — Endpoints
- BioMarin pauses Voxzogo dosing and enrollment across three Phase 2 label-expansion studies after slipped capital femoral epiphysis events surfaced in investigator-sponsored trials. — Endpoints
- CytomX reports positive interim Phase 1 expansion data for Varseta-M in colorectal cancer, helping support the stock's move and the company’s financing window. — BioPharma Dive
- FDA Commissioner Makary calls for IRB reform to accelerate U.S. trial starts and narrow the execution gap with China. — Endpoints
- AI drug discovery platforms are meeting a tougher investor bar as capital rotates toward clearer clinical proof and monetization paths. — BioSpace
- BioWorld rounds up the day’s regulatory actions. — BioWorld
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- Astellas exits its 2020 CytomX T-cell engager collaboration, ending a deal that carried $80M upfront and up to $1.6B in milestones. — Fierce Biotech
- BioCentury Deals Report: "Spring break for biotech deals?" — BioCentury
VC / Private Financings
- Unnatural Products raises $45M Series B to advance macrocyclic peptide therapeutics. Led by The Venture Collective; joined by argenx, Droia Ventures, Merck Global Health Innovation Fund, Artis Ventures and First Spark Ventures. — PR
- Alto Neuroscience announces a $120M PIPE to fund ALTO-207 through a planned Phase 3 in treatment-resistant depression. Led by Commodore Capital; joined by Dellora Investments, Driehaus Capital Management, Perceptive Advisors and Venrock Healthcare Capital Partners. — PR
IPOs / Follow-Ons
- CytomX launches a $250M public offering of common stock and pre-funded warrants, with Jefferies, Piper Sandler, Cantor and Barclays running the book. — PR
Academic Corner
- The AI co-scientist is here. — Nature Medicine
- First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. — Nature Medicine
|
|
That’s it for today — if your timeline got paused, at least your GPU order didn’t. See you tomorrow. BioBucks Team
|
|
|
